Engineered immune cells take on tough T-Cell cancers in early trial
NCT ID NCT06934382
First seen Jun 26, 2026 · Last updated Jul 08, 2026 · Updated 3 times
Summary
This early-phase study tests a new treatment called BEAM-201 for children and young adults with T-cell acute lymphoblastic leukemia or T-cell lymphoblastic lymphoma that has come back or not responded to standard treatments. BEAM-201 uses donor-derived immune cells that are engineered to recognize and attack cancer cells. The main goals are to find a safe dose and to see if the treatment can shrink tumors or lead to remission.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- BEAM-201 (allogeneic anti-CD7 CAR-T cells)
- What this could lead to
- If successful, this could offer a new treatment option for patients with hard-to-treat T-cell leukemia or lymphoma who have relapsed after other therapies.
- What could go wrong
- This is an early Phase 1 trial with only 33 participants, so safety and effectiveness are not yet proven. There are risks of severe side effects, including cytokine release syndrome and immune-related toxicities.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for RELAPSED/REFRACTORY T-CELL LYMPHOBLASTIC LYMPHOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Children's Hospital of Philadelphia
RECRUITINGPhiladelphia, Pennsylvania, 19104, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.